This article is within the scope ofWikiProject Companies, a collaborative effort to improve the coverage ofcompanies on Wikipedia. If you would like to participate, please visit the project page, where you can jointhe discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany
This article is within the scope ofWikiProject California, a collaborative effort to improve the coverage of theU.S. state ofCalifornia on Wikipedia. If you would like to participate, please visit the project page, where you can jointhe discussion and see a list of open tasks.CaliforniaWikipedia:WikiProject CaliforniaTemplate:WikiProject CaliforniaCalifornia
This article is within the scope ofWikiProject Pharmacology, a collaborative effort to improve the coverage ofPharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can jointhe discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
TheWikimedia Foundation'sTerms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; seeWP:PAID. For advice about reviewing paid contributions, seeWP:COIRESPONSE.
Chad Carlile: this person is not listed on the Amgen.com website.
The inclusion of this person is presumably based on information found in the Fall 2004 APSA Newsletter (seehttp://www.psychology.sdsu.edu/APSA_News_F-04.pdf) in which his role is described as follows: "Within Amgen, Chad works as a Senior Curriculum Designer at the organization’s headquarters in Thousand Oaks, CA. His group is part of a larger training function in the organization that trains new and existing employees on task- and product-specific qualities."
Removing this piece of information is a matter of addressing notability of content
I have not been able to find information that links a "Mark Hutt" or "Pritesh Patel" or "Hutt" or "P. Patel" to Amgen through basic searches with Google
Removing this piece of information is a matter of addressing verifiability of content
I am wondering if someone might know the reasoning why a search for "Immunex" redirects to this Amgen article? I ask this because Immunex (a Biotech R&D company) was founded in the 1980's and had quite a notable history of accomplishments before it was acquired by Amgen in 2001. If no one has any objections, I would like to set up an Immunex article, which can, of course, redirect the reader to the Amgen article, should they want to read more about the company by whom Immunex was acquired. Does anyone know how I can find out if there was formerly a Wiki article on Immunex? Thank you kindly.Tell someone (talk)02:00, 4 April 2009 (UTC)[reply]
The article has gone too far the other way now, the criticism section is the largest section of the article. And realistically the Sensipar trial can hardly be considered criticism - clinical trials have deaths. The wording alone is ambiguous; Sensipar is still available for use, it was dosages in children with ESRD that were being tested.Mc8755 (talk)23:01, 1 May 2013 (UTC)[reply]
Cyberbot II has detected that page contains external links that have either been globally or locally blacklisted.Links tend to be blacklisted because they have a history of being spammed, or are highly innappropriate for Wikipedia.This, however, doesn't necessarily mean it's spam, or not a good link.If the link is a good link, you may wish to request whitelisting by going to therequest page for whitelisting.If you feel the link being caught by the blacklist is a false positive, or no longer needed on the blacklist, you may request the regex be removed or altered at theblacklist request page.If the link is blacklisted globally and you feel the above applies you may request to whitelist it using the before mentioned request page, or request it's removal, or alteration, at therequest page on meta.When requesting whitelisting, be sure to supply the link to be whitelisted and wrap the link in nowiki tags.The whitelisting process can take its time so once a request has been filled out, you may set the invisible parameter on the tag to true.Please be aware that the bot will replace removed tags, and will remove misplaced tags regularly.
Below is a list of links that were found on the main page:
California Science Center article shows "Amgen Center for Science Learning", another wiki editor thought it was irrelevant on Amgen article and deleted it. Please discuss in Talk if compelled to further discuss this simple addition. Just trying to expand the better an article since another article already mentions it.Neoking (talk)23:39, 3 February 2016 (UTC)[reply]
Thanks for opening a discussion on Talk. The most important issue I had, is that source does not describe it as a separate building. Separately, it is also trivial with regard to everything Amgen does. Why is it important from your perspective? If there were an independent source about it (coverage in a newspaper or something) you would have a stronger case to make; it is difficult with a source like this to justify it.Jytdog (talk)23:44, 3 February 2016 (UTC)[reply]
Here is whatthe source you are citing says: "The Wallis Annenberg Building houses eight classrooms, administrative offices, a multi-purpose room and the school library. In addition, the Wallis Annenberg building includes over 80,000 square feet for the Science Center’s education division, the Amgen Center for Science Learning." This makes it really clear that the Amgen Center for Science Learning is inside the Wallis Annenberg Building" Now maybe that doesn't match reality (I don't know, i have never been there) but that is what the source you have provided says.Jytdog (talk)01:23, 4 February 2016 (UTC)[reply]
by the way,here is the content you wanted to add: ""Amgen Center for Science Learning", an Amgen Sponsored Building inCalifornia Science Center.[1]"
Do you see that you describe it as an "Amgen SponsoredBuilding"? (I am unsure what is up with the Germanic spelling, and I don't know why you put this in the external links section, and as I said above this would really need some kind of independent sourcing to show it is important enough to give any weight to....) but the key issue is that it is just wrong, based on the source.Jytdog (talk)01:55, 4 February 2016 (UTC)[reply]
Its funny how someone who thinks they are a Wikipedia Editor and don't know how to use Google Maps or MapQuest or the like to verify Wallis Annenberg Building (USC) is 2 blocks North of California Science Center/Exposition Park and not what I cited. But, its ok you can sit and guard dog your page and keep being a WikiTroll, ignorance is an excuse for reverting other peoples work. So you win by default, also its only a small contribution I tried to make. There are plenty of sources showing Amgen contributions.https://students.ucsd.edu/sponsor/amgen/#Other-Amgen-centers and there are plenty of online articles about Amgen generous donation to California Science Center and Dr. Theodore T. Alexander, Jr. Science Center School its easy to make others work but not do the work yourself. You can keep guard dogging your page all you want. Wikepedia is no longer a viable scholarly source due to people like you Jytdog. Its a shame how you feel so strongly about this article, have fun sitting on it.Neoking (talk)16:50, 4 February 2016 (UTC)[reply]
everything in WIkipedia is based on sources. I have reacted to the sources you brought and even quoted it above. You are not dealing with what it says, and I don't know what to do about that. I understand you are not happy with what it says but that is weird because you are the one who brought it. I just don't know what to do with that.Jytdog (talk)17:53, 4 February 2016 (UTC)[reply]
Thisedit request by an editor with a conflict of interest has now been answered.
Hi! I'm a conflict of interest editor for Amgen, a client of my employer, Porter Novelli. I have a quick edit request for this article: removing the “Controversy” paragraph about Amgen’s presence in Russia. Here’s my thinking:
TheYale report is a primary source, so ideally it should be supported by secondary media coverage of the same information (e.g. as inEmirates (airline)). I couldn’t find any independent media sources covering any kind of backlash or criticism against Amgen for its inclusion in the report.
I looked up many of the other organizations listed in the report, and from what I can tell, the only other organizations on the list with mentions in their articles had them added by either the sameIP user who added the section to this article orDiuuuuu, who added almost identical wording to several more articles. All of these edits date back to April 28/29, and I didn’t see any substantive discussion in talk in the few weeks since about use of the Yale source. Thereis some inconclusive discussion of the source atTalk:Corporate responses to the 2022 Russian invasion of Ukraine, whereDmitryShpak contends, "Yale team obviously did a lot of similar work and their list is over 450 records (some non-companies), BUT no links to company profile, expanded details, or citations make their list ambiguous at best."
If the reference is retained, I request that the phrase "Amgen refused to join the international community" be revised or deleted as interpretation of the source, since the source simply states that Amgen is still operating in Russia.
Additionally, if the reference is retained, two pieces of context I believe are relevant to include:
Amgen has donated $500,000 in disaster relief grants toInternational Medical Corps andProject Hope and provided matching funds for employee donations to select charities supporting humanitarian efforts in Ukraine.[1][2][3]
Many pharmaceutical companies have opted to continue operations in Russia or to suspend only some operations[4] in order to provide healthcare products and medicine to Russian people.[5]
Not done for now: The paragraph is appropriate given the circumstances, so this is denied. However, it could use some improvement.Quetstar (talk)00:43, 19 May 2022 (UTC)[reply]
@Quetstar: Thanks for the response! Would you please clarify how the paragraph is appropriate, given the concerns I raised about interpretation of a primary source? I want to understand what I'm missing here. Also, is there anything I can do to facilitate the improvement?Mary Gaulke (talk)16:56, 19 May 2022 (UTC)[reply]
The paragraph is appropriate in the sense that it describes Amgen's stance on Russia amidst its illegal invasion of Ukraine. Removing it would basically constitiute whitewashing. As for the improvements, the text should be reformatted to make it more compliant to standards.Quetstar (talk)11:04, 20 May 2022 (UTC)[reply]
@Quetstar: Understood. How about something like this?
During the2022 Russian invasion of Ukraine, Amgen was one of several pharmaceutical companies that opted to continue operations in Russia.[1][2] Research fromYale University updated on April 28, 2022, listed Amgen among the companies defying demands for exit or reduction of activities.[3] In March 2022, Amgen donated $500,000 in disaster relief grants toInternational Medical Corps andProject Hope and provided matching funds for employee donations to select charities supporting humanitarian efforts in Ukraine.[4][5][6]
Sorry for the delay, I'm quite busy right now, so I am deferring this to other editors. As for the paragraph you proposed, it looks good IMO, but i think that a second opinion from a more experienced editor will do the trick. You're welcome to make a new request at any time.Quetstar (talk)21:52, 2 June 2022 (UTC)[reply]
Part of an edit requested by an editor with aconflict of interest has been implemented. [see below]
Hi there! I have a COI: Amgen is a client of my employer, Porter Novelli. Requesting some edits to this article to provide a more complete reflection of the company's history as depicted in independent, reliable sources over the years.
Update the second mention of "Thousand Oaks, California" to just "Thousand Oaks" – not necessary to repeat the state two sentences in a row.
Update
Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer inVentura County.[1][2][3]
to
Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000[4] (8.5% of total city employment)[5] and included hundreds of scientists, making Amgen the largest employer inVentura County.[2][6] As of 2022, Amgen has approximately 24,000 staff[7] and, as of 2016, has a presence in approximately 100 countries. The company develops products in six therapeutic areas: cardiovascular disease,oncology, bone health,neuroscience,nephrology and inflammation.[8]
Given that the source is more than 20 years old, I think it's fair to say this isn't the best representation of the organization's current goals.
Update
In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases.
Thisedit request by an editor with a conflict of interest has now been answered.
Hi there! I have a COI: Amgen is a client of my employer, Porter Novelli. Requesting some edits to this article to provide a more complete reflection of the company's history as depicted in independent, reliable sources over the years.
Founded in Thousand Oaks, California, as Applied Molecular Genetics, Amgen was backed by a small group of venture capitalists. Its focus in early days was onrecombinant DNA technology and recombinant humaninsulin.[1]
Add to end of "1980" bullet:
In October, Amgen namedGeorge Rathmann its first president and chief executive officer.[1]
Add:
1983. On June 17, Amgen went public, selling two millioncommon shares and raising nearly $40 million.[2][3][4] That same year, after more than two years of work, an Amgen research team led byFu-Kuen Lin had a breakthrough in finding and cloning theerythropoietin gene, a protein created in the kidney that stimulatesred blood cell production. Lin's team created what would become Epogen (epoetin alfa).[5][6]
1984. In June, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.[7]
1988. In October,Gordon Binder was named CEO, succeeding George Rathmann.[10]
Update
1989. Amgen received approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure. Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certainHIV drugs, and for the reduction of the need for transfusions associated with surgery.[11]
to
1989. Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).[11][12]
The synopsis currently in the article doesn't reflect the product label.
Add:
1993. In March, Amgen opened a new manufacturing facility inPuerto Rico, which later became the company's flagship manufacturing site.[13]
1994. Amgen became the fifth company to receive theU.S. Department of Commerce'sNational Medal of Technology and Innovation, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.[14] Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).[15]
Add:
2000. In May, Kevin Sharer became Amgen's third CEO, following Gordon Binder's retirement.[16]
2001. Aranesp received FDA approval in September.[17]
2002. At the beginning of the year, the FDA approved Neulasta.[18] In July, Amgen acquired Immunex, the developer of Enbrel (etanercept).[19]
2004. Sensipar (cinacalcet) was approved by the FDA.[20][21] Also, Amgen acquired Tularik, another biotechnology company, expanding the company's research and development pipeline.[22][23]
2006. In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastaticcolorectal cancer.[24] Vectibix was approved by the FDA in September 2006.[25]
2011. Amgen acquired a manufacturing facility near Dublin, Ireland, in March.[28] In May, Amgen acquired BioVex,[29] developer of Imlygic (talimogene laherparepvec).[30] In December, Amgen andWatson Pharmaceuticals announced a collaboration to develop and commercialize severalbiosimilar medicines worldwide.[31]
Add:
2012. Amgen acquired Micromet, a company focused onBiTE technology, in March.[32] In May, Kevin Sharer retired, and Robert Bradway, formerly Amgen's president and chief operating officer, became CEO.[33] In June, Amgen acquired Turkish company Mustafa Nevzat Pharmaceuticals, expanding Amgen's presence in Turkey and nearby areas.[34] In July, Amgen acquired KAI Pharmaceuticals, developer of Parsabiv (etelcalcetide).[35][36] Amgen acquired Iceland-baseddeCODE Genetics in December.[37] Amgen also opened an affiliate in China.[38][39]
2014. In November, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.[41] Blincyto (blinatumomab) was approved by the FDA in December.[42][43]
Add to beginning of "2015" bullet:
Repatha (evolocumab) was approved by the FDA in August.[44]
Also in September, the FDA approved Amjevita (adalimumab-atto).[46]
Add to end of "2017" bullet:
The FDA approved Parsabiv in February[47] and Mvasi (bevacizumab-awwb) in September.[48] In October, the Amgen Foundation pledged $3 million toKhan Academy to support the development of free online biology lessons.[49][50]
In January, Evenity (romosozumab) received approval in Japan,[53][54] followed by FDA approval in April.[55] In June, Kanjinti (trastuzumab-anns) was approved by the FDA.[56]
Add to end of "2019" bullet:
In December, the FDA approved Avsola (infliximab-axxq).[57]
Add:
2020. In January, the Amgen Foundation andHarvard University debuted LabXchange, a free online science education platform.[58][59] Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.[60] In April, Amgen established Amgen K.K. as the company’s wholly-owned affiliate in Japan.[61][62] Amgen announced in July that theUnited States Court of Appeals for the Federal Circuit had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by theUnited States District Court for the District of New Jersey and rejectedSandoz's attempt to invalidate the patents on Enbrel.[63] Also in July, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.[64][65] Amgen joined theDow Jones Industrial Average on August 24, 2020.[66] In September, Amgen andEli Lilly and Company announced a global manufacturing collaboration forCOVID-19 antibody therapies.[67] On December 10, Amgen announced that it joined OneTen, a coalition of large employers that aims to hire and advance one million black Americans over the next ten years.[68] Later that month, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.[69]
Add to "2021" bullet, before "In July,":
The FDA approved Amgen'sLumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.[70] In June, Amgen andKyowa Kirin announced joint plans to develop and commercialize a treatment foratopic dermatitis.[71]
Add to end of "2021" bullet:
In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.[72][73] Amgen began construction on a new biomanufacturing plant inNew Albany, Ohio, in November.[74] In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severeasthma.[75] The FDA also approved Amgen's Otezla for adults with plaquepsoriasis of any severity level.[76]
Add to beginning of "2022" bullet:
In January, Amgen announced a research collaboration with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.[77][78] The company also launched a multi-target collaboration withArrakis Therapeutics to identify novel targeted RNA degrader therapeutics.[79][80] The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.[81][82] Also in February, Amgen issued its firstgreen bond to fund various environmentally friendly initiatives across the company.[83][84] The company broke ground on a new manufacturing facility inHolly Springs, North Carolina, in March.[85][86]
Thank you for your time and assistance.
References
^abWalsh, Robin (27 October 2010)."A history of: Amgen".pharmaphorum.com. Retrieved10 August 2022.
^Przepiorka, Donna; Ko, Chia-Wen; Deisseroth, Albert; Yancey, Carolyn L.; Candau-Chacon, Reyes; Chiu, Haw-Jyh; Gehrke, Brenda J.; Gomez-Broughton, Candace; Kane, Robert C.; Kirshner, Susan; Mehrotra, Nitin; Ricks, Tiffany K.; Schmiel, Deborah; Song, Pengfei; Zhao, Ping; Zhou, Qing; Farrell, Ann T.; Pazdur, Richard (15 September 2015)."FDA Approval: Blinatumomab".Clinical Cancer Research: An Official Journal of the American Association for Cancer Research.21 (18):4035–4039.doi:10.1158/1078-0432.CCR-15-0612.ISSN1557-3265. Retrieved11 August 2022.
An impartial editor has reviewed the proposed edit(s) and asked the editor with a conflict of interest to go ahead and make the suggested changes.
Hi there! I have a COI: Amgen is a client of my employer, Porter Novelli. Requesting some edits to this article to provide a more complete reflection of the company's history as depicted in independent, reliable sources over the years.
Lastly, add the following line after the last sentence in the lead to give a fuller picture of the company's breadth (these products are substantiated in the article body):
As of August 2022, Amgen had 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I.[13]
I think it makes sense to move all the info from November 2014 and March 2015 to the Timeline section, since those candidates are no longer in the pipeline. Since Aimovig's approval is mentioned earlier in the article, it might make sense to just delete it from here as well.
In August 2020, Amgen,Takeda, andAbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.[14]
In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (includingimmunotherapy and/or chemotherapy).[15] Amgen, the Global Coalition for Adaptive Research, andEisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.[16][17]
In November 2020, Amgen, Takeda, andUCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.[18] Amgen also announced that it would terminate its collaboration withCytokinetics and transition the development and commercialization rights foromecamtiv mecarbil and AMG 594.[19] Amgen andAstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicinetezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.[20]
In December 2020, the FDA grantedbreakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.[21]
Not done for now: The paragraph is appropriate given the circumstances, so this is denied. However, it could use some improvement.Quetstar (talk)00:43, 19 May 2022 (UTC)[reply]
Partly done: "Other marketed products" were not included because they are not supported by areliable source.Throast{{ping}} me! (talk |contribs)16:07, 26 June 2023 (UTC)[reply]
Go ahead: I have reviewed these proposed changes and suggest that you go ahead and make the proposed changes to the page.Mattdaviesfsic (talk)19:42, 28 June 2023 (UTC)[reply]